AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01868594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subetta
Description: Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study NCT01868594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study NCT01969305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kazakhstani Family Together
Description: Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
Study NCT01969305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Alone
Description: Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~1. Facts and Myth about HIV. HIV/STIs modes of transmission;~2. Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~3. Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use.
Study NCT02256345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KNO3
Description: Active Comparator
Study NCT02256345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KCl
Description: Placebo Comparator
Study NCT02907801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perception-Action Approach
Description: Environmental set-up, gentle manual guidance, and caregiver education
Study NCT01542294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s1
Description: 60-90mg/m2/d P.O. day 1-14, repeated every 21 days
Study NCT01542294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 d1 repeated every 21 days
Study NCT03288311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized post-extubation respiratory support
Description: Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
Study NCT03288311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
Study NCT00005577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT02349776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing testimonies from survivors of transplants to patients
Description: Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant.
Study NCT00691054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
Study NCT00515554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: addition of Rituximab to BEACOPP escalated
Study NCT00515554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEACOPP escalated
Description: chemotherapy with BEACOPP escalated
Study NCT00515554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP escalated
Description: chemotherapy with BEACOPP escalated
Study NCT02444806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full polysomnography
Description: Full sleep and respiratory monitoring with EEG
Study NCT02444806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oximetry-capnography
Description: Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
Study NCT00096824 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurological assessment
Description: All participants will undergo neurological examinations and neuropsychological assessments.
Study NCT01739374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reduced mesh implants
Description: mesh for pelvic floor reinforcement
Study NCT03746145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 1714
Description: This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.
Study NCT03746145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo sachet containing maltodextrin and magnesium stearate.
Description: placebo sachet containing maltodextrin and magnesium stearate.
Study NCT02296905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
Study NCT02296905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
Study NCT02299700 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
Study NCT02314156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study NCT02314156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telapristone Acetate
Description: Given PO
Study NCT04810949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamine D3 supplementation
Description: 1. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
Study NCT02314156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given transdermally
Study NCT04810949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet and sun exposure
Description: 2. Hygienic-dietary recommendations will consist of 2 steps~1. Sun exposure at least 10 minutes a day from 10: 00-6: 00 pm~2. Consumption of foods rich in vitamin D: milk, fish, almonds, mushrooms
Study NCT02459535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation glucose
Description: oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
Study NCT02459535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation saccharin
Study NCT02459535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation aspartame
Study NCT02459535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation sucralose
Study NCT01807286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I.
Study NCT01807286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
Study NCT01807286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
Study NCT01807286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
Study NCT00471289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA with placement of paclitaxel-eluting stent
Description: PTA with placement of paclitaxel-eluting stent
Study NCT00471289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: PTA
Study NCT03666650 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban 60 MG
Description: Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
Study NCT03204708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter
Description: catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
Study NCT02744014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Add-on Therapy for Axial Spondyloarthritis
Study NCT02744014 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Add-on Therapy for Axial Spondyloarthritis
Study NCT02309502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Pascal
Description: Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants
Study NCT02309502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yellow Pascal
Description: : Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants
Study NCT01250301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-nicotinised cigarettes + standard treatment
Description: Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.~Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline).
Study NCT01250301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Participants will receive standard treatment from the NHS Stop Smoking Service.
Study NCT02314156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03204708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv analgesia
Description: patients were given 100 ml of tramadol 30 minutes before extubation
Study NCT04277052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination muscles sections by Ultrasonography
Description: Determination muscles sections by Ultrasonography
Study NCT03551106 — intervention group
Intervention type: OTHER
Intervention: Web based learning module
Description: Web based learning module available on a especially designed website
Study NCT00833885 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Masks
Description: Wearing of surgical masks
Study NCT00833885 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Masks & hand hygiene
Description: Wearing of surgical masks and intensified hand washing
Study NCT00833885 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: General information about virus transmission in households and basic means to prevent it
Study NCT01163045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thyroidectomy
Description: total thyroidectomy and lobectomy
Study NCT03782116 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical stimulation (Elitone)
Description: Transcutaneous perineal area electrical stimulation
Study NCT03782116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (Elitone)
Description: Transcutaneous perineal area electrical stimulation
Study NCT03478202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GOLO RELEASE
Description: GOLO RELEASE plus Diet
Study NCT01998529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
Study NCT01998529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
Study NCT00967668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small change approach to improve physical activity and diet
Description: The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle.
Study NCT00967668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOVE! Usual Care
Description: The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI
Description: Proton Lung Magnetic Resonance Imaging
Study NCT04036513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MINST
Description: For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes.
Study NCT02314156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02314156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02314156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03839225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community intervention
Description: Community intervention will be built depending on contextual factors and will contain the following elements:~* Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~* The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~* Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions.
Study NCT02422693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercises
Description: Exercises performed in the water.
Study NCT02422693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Exercises
Description: Exercises performed in the water.
Study NCT02422693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep-water running
Description: It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
Study NCT04036513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional SRP
Description: Scaling and root planing with conventional instruments.
Study NCT02000219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes
Description: The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
Study NCT01595308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Pomegranate juice
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium MRI
Description: Sodium Soft Tissue Magnetic Resonance Imaging
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CT
Description: High-resolution Quantitative Chest CT
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic 2D Speckle-Tracking Echocardiography
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional Exhaled Nitric Oxide
Description: Fractional Exhaled Nitric Oxide testing
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests
Description: Spirometry and Plethysmography
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
Study NCT01207609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Gastric Plication
Description: The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
Study NCT01309997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six-Minute Walk Test
Description: Six-Minute Walk Test
Study NCT03773991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dyspnea Questionnaires
Description: Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
Study NCT01309997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT02807389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC Fistula Plug
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
Study NCT00779714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC (dacarbazine)
Description: 1000 mg/m2, d1 every 21 days